U.S. Markets open in 5 hrs 32 mins

Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity

·1 min read
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate.

  • Sales decreased 44% to $2.85 billion, surpassing the analysts' consensus of $2.79 billion.

  • Total revenues excluding REGEN-COV and Ronapreve revenues increased by 20%. No REGEN-COV sales were recorded as the company had completed its final deliveries under its agreements with the U.S. government.

  • Q2 U.S. Eylea sales increased 14% Y/Y to $1.62 billion.

  • The company obtained the exclusive right to Libtayo from Sanofi SA (NASDAQ: SNY) for a $900 million up-front payment. Sanofi is eligible to receive a $100 million regulatory milestone and $100 million in sales-based milestones.

  • Concurrently, Regeneron announced initial data from an ongoing Phase 1/2 trial of REGN5678 in combination with Libtayo (cemiplimab) in advanced metastatic castration-resistant prostate cancer.

  • Preliminary data showed dose-dependent anti-tumor activity.

  • At the lowest dose levels (cohorts 1-5), there was almost no evidence of anti-tumor activity, with only 1 of 17 patients showing a decrease (22%) in prostate-specific antigen.

  • At the higher dose levels (cohorts 6-8), evidence of dose-dependent anti-tumor activity was generally seen within six weeks of starting combination treatment.

  • Price Action: REGN shares are up 8.16% at $621.88 during the market session on the last check Wednesday

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.